Alliances
PureTech, which has headquarters in Boston, but is listed in London, signed a research collaboration deal with Germany’s Boehringer Ingelheim. The companies will work to develop novel product candidates using PureTech’s proprietary lymphatic targeting technology for immune modulation.
Under terms of the deal, Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development against these targets.
There is a tendency to look at biotech as being all about developing drugs. And, of course, that is the primary focus of BioSpace. However, from time to time it’s a good idea to remind ourselves that biotech can and does have broader applications besides medicines, and can, in fact, impact our daily lives on a regular basis.
The companies will collaborate on a clinical trial to combine Novo Nordisk’s semaglutide and Gilead’s cilofexor and firsocostat for treatment of NASH.
The collaboration leverages indivumed’s true multi-omics cancer database “Indivutype” and evotec’s drug discovery platforms to identify new therapeutics for colorectal cancer
Pharma and biotech companies from Asia to Europe provide updates on business and clinical activities.
Only a few weeks after Concerto HealthAI inked a deal with Bristol-Myers Squibb, it has signed a similar deal with Pfizer.
San Francisco-based Audentes Therapeutics signed a licensing agreement and collaboration deal with Nationwide Children’s Hospital to expand its pipeline for vectorized antisense treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).
Under the terms of the agreement, Regeneron is paying $400 million upfront to Alnylam and acquiring another $400 million in equity at a price per share of $90, or 4.44 million common shares.
The recent CBRE Research report, “2019 U.S. Life Sciences Clusters” has two Texas metropolitan areas in its top-10 fastest-growing life sciences market. Houston ranked third, while Dallas/Ft. Worth ranked seventh. Let’s look at Dallas/Ft. Worth.
PRESS RELEASES